The US FDA has approved an investigational new drug (IND) application and granted fast track designation (FTD) for CBI-1214, a T-cell engager being developed for the treatment of patients with colorectal cancer.1
FTD is designed to facilitate the…
The US FDA has approved an investigational new drug (IND) application and granted fast track designation (FTD) for CBI-1214, a T-cell engager being developed for the treatment of patients with colorectal cancer.1
FTD is designed to facilitate the…